Register for our free email digests:
Division of AMAG Pharmaceuticals Inc.
Latest From Ther-Rx Corp.
During a hearing in the company’s lawsuit against FDA, a federal judge repeatedly questions her authority to require the agency take enforcement action against compounding pharmacies; KV filed for bankruptcy protection three days earlier, citing its inability to realize full value of the pre-term birth drug due to competition from cheaper compounded versions of 17-P.
The agency says its decisions not to take enforcement action against pharmacies compounding hydroxyprogesterone are discretionary and that KV has not shown that payers are likely to change their reimbursement policies if the court follows its request.
KV seeks a court order requiring FDA to desist from permitting importation of unapproved API for compounded hydroxyprogesterone and to state its intent to take enforcement action against compounders.
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- AMAG Pharmaceuticals Inc.
- Senior Management
- Gregory Divis, Pres.
- Contact Info
Phone: (314) 646-3700
1 Corp. Woods Dr.
Bridgeton, MO 63044
You must sign in to use this functionality
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.